We claim:

1. A dry powder inhaler comprising:

a housing;

a body comprising a mouthpiece integrally configured with the body;

wherein the body comprises a mounting area for a cartridge, and the body and the housing are movable relative to one another linearly and are operably configured to engage one another by insertion to effectuate the cartridge to be reconfigured to attain an airflow pathway for discharging a powder dose upon an inhalation; and

wherein the dry powder inhaler further comprises a dry powder including a cannabinoid in an amount from 1% to 40% (w/w), a phospholipid, and 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine.

2. The dry powder inhaler of claim 1, wherein the mouthpiece has an air inlet for communicating with an interior compartment of the inhaler body; or wherein the mouthpiece further has an internal volume extending from the first inlet port to the exit port, wherein the internal volume is greater than 0.2 cubic centimeters.

3. The dry powder inhaler of claim 1, wherein the housing reconfigures the cartridge installed in the inhaler by translation of the housing over the inhaler body from an open configuration to a closed configuration.

4. The dry powder inhaler of claim 1, wherein the movement of the housing relative to the body is facilitated by guide rails structured along a longitudinal axis and extending from right side and/or left side of the inhaler body.

5. The dry powder inhaler of claim 1, wherein the dry powder inhaler is configured to attain an open or loading position, and a closed or dosing position.

6. The dry powder inhaler of claim 1, wherein the housing further comprises a protruding rigid element which pushes the cartridge to a dosing position from a containment configuration.

7. The dry powder inhaler of claim 1, wherein the inhaler is further configured to have rigid flow conduits.

8. The dry powder inhaler of claim 1, wherein the housing comprises a cover which envelops a portion of the inhaler body.

9. The dry powder inhaler of claim 1, wherein the inhaler body comprises detents which prevent separation of the body from the housing in an assembled inhaler.

10. The dry powder inhaler of claim 1, wherein the housing positions the cartridge to align with the mouthpiece by translation of the housing over the inhaler body from an open configuration to a closed configuration.

11. The dry powder inhaler of any of the preceding claims, wherein the dry powder is a pharmaceutical composition for inhalation.

12. The dry powder inhaler of any of the preceding claims, wherein the cannabinoid is tetrahydrocannabinol or cannabidiol.

13. The dry powder inhaler of any of the preceding claims, wherein the phospholipid is selected from 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine and 1,2-distearoyl-*sn*-glycero-3-phosphocholine.